Trial Profile
A randomized phase II trial to evaluate the efficacy and safety of vandetanib (ZD6474, Zactima) versus vinorelbine in patients with inoperable or relapsed malignant mesothelioma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2016
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Vinorelbine
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 30 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from 1 Dec 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 14 Feb 2008 New trial record.